Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | QDPR | P09417 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17643421 | 1.00 | EPHX2 (0.40) | EPHX2CHRNB2CHRNA3CHRNA4EPHX1 | |
| SCHEMBL21325280 | 0.88 | CYP1A2 (0.50) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL22849809 | 0.87 | ALDH1A1 (0.42) | EPHX2CHRNB2CHRNA3CHRNA4EPHX1 | |
| SCHEMBL18557206 | 0.87 | ALDH1A1 (0.42) | EPHX2CHRNB2CHRNA3CHRNA4EPHX1 | |
| SCHEMBL6631511 | 0.83 | CHRNB2 (0.54) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL15431463 | 0.83 | EPHX2 (0.38) | EPHX2CHRNB2CHRNA3CHRNA4EPHX1 | |
| SCHEMBL16727358 | 0.83 | EPHX2 (0.38) | EPHX2CHRNB2CHRNA3CHRNA4EPHX1 | |
| SCHEMBL14034733 | 0.82 | ALDH1A1 (0.36) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL23624210 | 0.81 | EPHX2 (0.37) | EPHX2CHRNB2CHRNA3CHRNA4EPHX1 | |
| SCHEMBL16169058 | 0.81 | EPHX2 (0.37) | EPHX2CHRNB2CHRNA3CHRNA4EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3760632-B1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF | Simcere pharmaceutical co ltd (CN) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023116934-A1 | KRASG12D PROTEIN HYDROLYSIS REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州泽璟生物制药股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-11678659-B2 | Use as rodenticides of compounds that inhibit blood coagulation | GULBA DIETRICH (DE) | 2023-06-20 | — | — | US | disclosed |
| US-11464780-B2 | Pyrazolopyrimidine derivative and use thereof | SIMCERE PHARMACEUTICAL CO. LTD. (CN) | 2022-10-11 | — | — | US | disclosed |
| WO-2022188819-A1 | SOS1 PROTEOLYSIS MODULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 苏州泽璟生物制药股份有限公司 | 2022-09-15 | — | — | WO | disclosed |
| EP-3230281-B1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AG (DE) | 2021-05-26 | — | — | EP | disclosed |
| EP-3760632-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF | Medshine Discovery Inc. (CN) | 2021-01-06 | — | — | EP | disclosed |
| US-20200405725-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2020-12-31 | — | — | US | disclosed |
| WO-2020207352-A1 | TRIAZINE BENZIMIDAZOLE COMPOUNDS AND MEDICAL USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2020-10-15 | — | — | WO | disclosed |
| US-10265310-B2 | 6-membered cyclic amines or lactames substituted with urea and phenyl | Grünenthal GmbH (DE) | 2019-04-23 | — | — | US | disclosed |
| US-8883828-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130065901-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011150356-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-8022223-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100105659-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPPHARMA INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-0974602-B1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR CORP (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6291596-B1 | CONTACTING OLEFINICALLY UNSATURATED COMPOUND WITH HYDROGEN IN THE PRESENCE OF A HYDROGENATION CATALYST COMPRISING TITANIUM OR ZIRCONIUM OR HAFNIUM COMPOUND IN AN INERT, ORGANIC SOLVENT | JSR CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0974602-A1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR Corporation (JP) | 2000-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | EPHX2 2695/4885CHRNB2 4866/4885CHRNA3 4875/4885 |
| US-20200405725-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF | TPMT, VHL, GOT2 | EPHX2 3789/4885CHRNB2 4840/4885CHRNA3 4870/4885 |
| US-20100105659-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | EPHX2 4564/4885CHRNB2 2910/4885CHRNA3 3044/4885 |
| US-11678659-B2 | Use as rodenticides of compounds that inhibit blood coagulation | PLAT, F2R, PLAUR | EPHX2 1101/4885CHRNB2 1038/4885CHRNA3 875/4885 |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, PRKCSH | EPHX2 4703/4885CHRNB2 2322/4885CHRNA3 2702/4885 |
| US-10265310-B2 | 6-membered cyclic amines or lactames substituted with urea and phenyl | FPR2, FPR1, FPR3 | EPHX2 693/4885CHRNB2 1047/4885CHRNA3 2456/4885 |
| US-20130065901-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | EPHX2 4564/4885CHRNB2 2910/4885CHRNA3 3044/4885 |
| US-11464780-B2 | Pyrazolopyrimidine derivative and use thereof | TPMT, VHL, GOT2 | EPHX2 3789/4885CHRNB2 4840/4885CHRNA3 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.